Empowered Funds LLC Has $5.94 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Empowered Funds LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,408 shares of the medical research company’s stock after buying an additional 1,720 shares during the period. Empowered Funds LLC’s holdings in Thermo Fisher Scientific were worth $5,935,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in TMO. AMF Tjanstepension AB bought a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $42,409,000. Exchange Traded Concepts LLC lifted its holdings in Thermo Fisher Scientific by 8.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 2,137 shares of the medical research company’s stock worth $1,322,000 after purchasing an additional 159 shares during the last quarter. Redhawk Wealth Advisors Inc. acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at $218,000. CX Institutional increased its position in Thermo Fisher Scientific by 554.3% during the 3rd quarter. CX Institutional now owns 7,898 shares of the medical research company’s stock worth $4,885,000 after buying an additional 6,691 shares during the period. Finally, Creative Planning boosted its position in shares of Thermo Fisher Scientific by 3.1% in the third quarter. Creative Planning now owns 101,174 shares of the medical research company’s stock valued at $62,583,000 after acquiring an additional 3,072 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares in the company, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,125 shares of company stock valued at $11,231,699. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 1.4 %

TMO opened at $545.27 on Wednesday. The firm has a market capitalization of $208.57 billion, a price-to-earnings ratio of 32.99, a PEG ratio of 3.18 and a beta of 0.77. The company’s 50 day moving average price is $547.81 and its two-hundred day moving average price is $571.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

TMO has been the subject of several analyst reports. Bank of America dropped their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Stifel Nicolaus reduced their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. UBS Group upped their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a research note on Friday, January 10th. Finally, Wells Fargo & Company raised their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $658.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.